Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

计划入组 15 人 · 首次发布于 2019 年 8 月 14 日

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

计划入组 48 人 · 首次发布于 2022 年 11 月 8 日

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

计划入组 365 人 · 首次发布于 2022 年 3 月 31 日

IHMT-IDH1-053

IDH1 targeting vaccine

IDH1 inhibitors (Zhejiang Meton)

Aprea Therapeutics

United States

Kura Oncology

United States

Rein Therapeutics

Nuvation Bio Initiates Phase 3 Trial of Safusidenib for High-Grade IDH1-Mutant Glioma Maintenance Treatment

Vorasidenib Shows Promise as First Targeted Therapy for IDH-Mutant Low-Grade Gliomas

FDA Approves Vorasidenib as Targeted Therapy for IDH-Mutant Gliomas